Jun, 2011

U.S.A.
News / Therapeutic Area News
Tarceva Nearly Doubled the Time People With a Genetically Distinct Type of Lung Cancer Lived Without Their Disease Getting Worse
SOUTH SAN FRANCISCO, Calif. – June 2, 2011 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Astellas Pharma US, Inc. (“Astellas”), today announced results of...
Read More

May, 2011

U.S.A.
News / Therapeutic Area News
Astellas Announces Positive Phase III Results Showing Mirabegron Improves Key OAB Symptoms
Astellas Pharma US, Inc. ("Astellas Pharma US"), U.S. subsidiary of Astellas Pharma Inc. (Tokyo: TSE: 4503, "the Company"), today announced the...
Read More

Jan, 2011

U.S.A.
News / Therapeutic Area News
Early Successful Readout of Tarceva Study in a Distinct Form of Lung Cancer Early Successful Readout of Tarceva Study in a Distinct Form of Lung Cancer
SOUTH SAN FRANCISCO, Calif., MELVILLE, New York and TOKYO – January 27, 2011 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and OSI Pharmaceuticals, a wholly owned...
Read More

Sep, 2010

U.S.A.
News / Therapeutic Area News
Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Radiology 2010
PHILADELPHIA, PA, September 25, 2010 – Today Astellas Pharma US, Inc., (“Astellas”) announced results of a Phase IV study showing Lexiscan® (regadenoson) Injection was comparable to placebo...
Read More
U.S.A.
News / Therapeutic Area News
New Smartphone App Launches For Cardiac Imaging Test
PHILADELPHIA, PA, September 24, 2010 - Today Astellas Pharma US, Inc. ("Astellas") announced the Launch of the Appropriate Use Criteria (AUC) for Cardiac Radionuclide Imaging application (app) for...
Read More